11 March 2019 – Takis appears on Il Corriere della Sera newspaper
This week "Il Corriere della Sera" published an article in the Biotechnology section describing our product Rever3mAb. This is a monoclonal antibody able to “revert” resistance to conventional anticancer therapies.
Research on biological drugs is expected to revolutionize cancer treatment: we are working hard to bring Rever3mab to clinical practice, in order to really make a change in the life of patients.
The article also mentions VITARES and our committment to raise people’s awareness of the importance of scientific and translational research for the implementation of effective anticancer therapies.
We are proud to coordinate this amazing project!
For more information: Progetto: REVER3MAB - UE, Stato e Regione